A Phase 3 interventional study of mRNA-1010 and Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine in Seasonal Influenza, sponsored by ModernaTX, Inc.. Completed at 103 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-10.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human — 2 open to participants now, 2 under way, none of them phase 3. mRNA-1010 influenza vaccine · Influenza, Human.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, this one is the 3rd largest by enrollment, is one of 2 that started in 2023, is one of 4 in phase 3, and was the 8th registered.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
Browse Influenza, Human studies →2 of the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 65+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 9–17 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 123 Influenza, Human studies recruiting now, 66 (54%) set no upper age limit and 47 (38%) stop at 75 or younger; 34 take children under 18; 68 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 4 · Phase 3 4 · Phase 4 1
First in 2021; this study’s year is marked. 2 started in 2023.
This study's enrollment of 8,411 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Median enrollment 471 across the 12 interventional studies. Of the 10 that completed or were terminated, 7 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
23 studies in Influenza, Human by Moderna, Inc.: 2 open now, 3 under way, 1 of them phase 3. Of 20 finished, 12 (60%) have results posted.
Among the 23 studies in Influenza, Human by Moderna, Inc., this one is the 3rd largest by enrollment, is one of 6 that started in 2023, is one of 7 in phase 3, and was the 12th registered.
Moderna, Inc.’s Influenza, Human studies by the year they started, since 2015.
1 of the studies testing mRNA-1010 influenza vaccine in Influenza, Human that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07884175ModernaTX, Inc.A Study of Updated mRNA Seasonal Influenza Vaccines | 2026-12-07 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing mRNA-1010 influenza vaccine in Influenza, Human, from their registry updates:
Among Moderna, Inc.’s 23 in Influenza, Human:
This tab as a report to print or save as PDF → With an account.
This study includes 3 parts: Parts A, B, and C. The purpose of this study is to evaluate the immunogenicity and safety of mRNA-1010 seasonal influenza vaccine in adults.
2,360 studies on the registry are indexed under Influenza, Human; 185 are open to participants now.
This study's enrollment of 8,411 is above the median of 228 across 1,959 interventional studies indexed under Influenza, Human.
Browse Influenza, Human studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within Influenza, Human, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Virus Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Part A:
Part B:
Part C:
Exclusion Criteria:
Note: Other inclusion and exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of mRNA-1010 by intramuscular (IM) injection on Day 1.
Biological: mRNA-1010
Participants will receive a single dose of licensed quadrivalent inactivated seasonal influenza vaccine by IM injection on Day 1.
Biological: Licensed Quadrivalent Inactivated Seasonal Influenza Vaccine
Sterile liquid for injection
Also known as: Seasonal influenza vaccine
Sterile suspension for injection
Also known as: Fluarix Quadrivalent, Fluzone HD
Geometric Mean Titer (GMT) of Anti-Hemagglutinin (HA) Antibody Levels as Measured by Hemagglutination Inhibition (HAI)
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ.
Time frame: Day 29
Percentage of Participants Reaching Seroconversion, as Measured by HAI
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Seroconversion rate was defined as the percentage of participants with either a Baseline HAI titer \<1:10 and a postbaseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in postbaseline HAI antibody titer. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were converted to the ULOQ.
Time frame: Day 29
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs, representative of vaccine reactogenicity, were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Per prespecified analysis, only solicited ARs that were assessed and confirmed by the Investigator as both serious and related to IP were recorded as an adverse event. These adverse events were recorded as a serious AE (SAE) and are included in the summary of SAEs in the "Reported Adverse Events" section.
Time frame: Up to 7 days after study injection
Number of Participants With Unsolicited Adverse Events (AEs)
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs included any AE not collected as a solicited AR, and also included solicited ARs assessed and confirmed as both serious and related by the Investigator. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Up to 28 days after study injection
Number of Participants With Medically Attended Adverse Events (MAAEs), Adverse Events of Special Interest (AESIs), SAEs, and AEs Leading to Discontinuation
An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
Time frame: Day 1 through Day 181
Percentage of Participants With HAI Titer ≥1:40
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains.
Time frame: Day 29
Geometric Mean Fold-Rise (GMFR) of Postinjection Anti-HA Antibodies for Influenza, as Measured by HAI Assay
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. The GMFR measured the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
Time frame: Baseline (Day 1) to Day 29
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Day 1 through Day 181
| Milestone | Part A: Fluarix Quadrivalent Influenza Vaccine (QIV) | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone High Dose (HD) QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Started | 1189 | 1225 | 1494 | 1500 | 1496 | 1507 |
| Safety set | 1180 | 1220 | 1488 | 1492 | 1490 | 1502 |
| Completed | 1106 | 1113 | 1425 | 1434 | 1456 | 1484 |
| Not completed | 83 | 112 | 69 | 66 | 40 | 23 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Death | 1 | 5 | 2 | 3 | 1 | 3 |
| Withdrew: Lost to follow-up | 57 | 88 | 54 | 47 | 25 | 10 |
| Withdrew: Noncompliance with study procedures | 0 | 1 | 1 | 1 | 1 | 0 |
| Withdrew: Physician decision | 2 | 0 | 1 | 2 | 1 | 1 |
| Withdrew: Protocol violation | 5 | 2 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 17 | 16 | 10 | 12 | 10 | 9 |
| Withdrew: Other than specified | 0 | 0 | 1 | 0 | 2 | 0 |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Antibody values reported as below lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were converted to the ULOQ.
| titer | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 147.49 (138.07 to 157.55) | 220.17 (207.30 to 233.84) | 137.90 (129.89 to 146.40) | 208.10 (196.43 to 220.47) | 130.09 (122.86 to 137.74) | 174.81 (165.15 to 185.04) |
| Influenza A H3N2 Antibody | 107.21 (101.11 to 113.68) | 152.56 (144.13 to 161.48) | 97.18 (91.74 to 102.95) | 157.88 (148.45 to 167.91) | 116.24 (109.47 to 123.44) | 141.62 (133.29 to 150.46) |
| Influenza B/Victoria Antibody | 155.94 (147.78 to 164.55) | 198.55 (188.44 to 209.22) | 150.90 (144.37 to 157.73) | 196.71 (187.68 to 206.17) | 195.97 (187.44 to 204.89) | 248.03 (237.34 to 259.21) |
| Influenza B/Yamagata Antibody | 146.63 (138.91 to 154.78) | 182.94 (173.61 to 192.76) | 113.76 (109.21 to 118.51) | 158.58 (151.55 to 165.93) | 91.94 (88.33 to 95.71) | 104.82 (100.70 to 109.11) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. Seroconversion rate was defined as the percentage of participants with either a Baseline HAI titer \<1:10 and a postbaseline titer ≥1:40 or a Baseline HAI titer ≥1:10 and a minimum 4-fold rise in postbaseline HAI antibody titer. Antibody values reported as below LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were converted to the ULOQ.
| percentage of participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 34.9 (32.12 to 37.74) | 50.2 (47.32 to 53.10) | 45.0 (42.42 to 47.65) | 64.4 (61.87 to 66.88) | 36.3 (33.75 to 38.84) | 49.7 (47.06 to 52.31) |
| Influenza A H3N2 Antibody | 32.2 (29.45 to 34.96) | 51.1 (48.17 to 53.94) | 44.0 (41.37 to 46.59) | 66.4 (63.91 to 68.85) | 47.8 (45.20 to 50.48) | 56.4 (53.80 to 59.02) |
| Influenza B/Victoria Antibody | 17.0 (14.86 to 19.32) | 26.6 (24.09 to 29.20) | 18.4 (16.39 to 20.48) | 33.0 (30.54 to 35.46) | 20.2 (18.09 to 22.35) | 29.8 (27.46 to 32.27) |
| Influenza B/Yamagata Antibody | 24.7 (22.19 to 27.29) | 33.2 (30.57 to 36.01) | 23.4 (21.25 to 25.71) | 35.6 (33.12 to 38.13) | 20.2 (18.09 to 22.35) | 26.0 (23.77 to 28.40) |
Solicited ARs, representative of vaccine reactogenicity, were collected in an electronic diary (eDiary). Local ARs: injection site pain, erythema (redness), swelling/induration (hardness); and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs: fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Per prespecified analysis, only solicited ARs that were assessed and confirmed by the Investigator as both serious and related to IP were recorded as an adverse event. These adverse events were recorded as a serious AE (SAE) and are included in the summary of SAEs in the "Reported Adverse Events" section.
| Participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs) | 682 | 1060 | 796 | 1158 | 734 | 1131 |
An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Unsolicited AEs included any AE not collected as a solicited AR, and also included solicited ARs assessed and confirmed as both serious and related by the Investigator. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited Adverse Events (AEs) | 134 | 145 | 134 | 147 | 137 | 155 |
An MAAE was an AE that led to an unscheduled visit to a healthcare practitioner. An AESI was an AE (serious or nonserious) of scientific and medical concern specific to the Sponsor's product or program, for which ongoing monitoring and immediate notification by the Investigator to the Sponsor was required. An SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability, was a congenital anomaly/birth defect, or was an important medical event. A summary of SAEs and all nonserious AEs ("Other"), regardless of causality, is located in the "Reported Adverse Events" section.
| Participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| MAAEs | 195 | 226 | 223 | 217 | 248 | 257 |
| AESIs | 2 | 1 | 0 | 1 | 1 | 2 |
| SAEs | 21 | 27 | 22 | 25 | 38 | 41 |
| AEs Leading to Discontinuation | 1 | 0 | 0 | 1 | 0 | 0 |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains.
| percentage of participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 93.7 (92.17 to 95.08) | 96.7 (95.53 to 97.65) | 92.0 (90.47 to 93.36) | 96.4 (95.29 to 97.29) | 92.3 (90.82 to 93.67) | 96.5 (95.40 to 97.38) |
| Influenza A H3N2 Antibody | 92.0 (90.25 to 93.50) | 97.0 (95.92 to 97.93) | 86.4 (84.51 to 88.13) | 92.6 (91.17 to 93.94) | 88.9 (87.10 to 90.45) | 92.8 (91.38 to 94.13) |
| Influenza B/Victoria Antibody | 99.3 (98.62 to 99.70) | 99.7 (99.14 to 99.91) | 99.4 (98.90 to 99.76) | 99.4 (98.82 to 99.71) | 99.5 (98.98 to 99.80) | 100 (99.74 to 100.00) |
| Influenza B/Yamagata Antibody | 97.5 (96.45 to 98.35) | 98.5 (97.61 to 99.10) | 97.4 (96.44 to 98.17) | 97.8 (96.88 to 98.48) | 93.7 (92.28 to 94.90) | 96.1 (95.01 to 97.08) |
Influenza A strains included H1N1 and H3N2 and influenza B strains included Victoria and Yamagata strains. The GMFR measured the changes in immunogenicity titers or levels from Baseline within participants. Seasonal influenza A included H1N1 and H3N2 and seasonal influenza B strains included Victoria-lineage and Yamagata-lineage. Fold-rise was calculated by dividing post-vaccination results by the baseline value. 95% confidence interval (CI) for GMFR was calculated based on the t-distribution of the differences in the log-transformed values between analysis timepoint and baseline, then back transformed to the original scale for presentation.
| ratio | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Influenza A H1N1 Antibody | 2.78 (2.59 to 2.99) | 4.03 (3.80 to 4.27) | 3.29 (3.10 to 3.49) | 4.99 (4.73 to 5.26) | 2.60 (2.47 to 2.74) | 3.49 (3.32 to 3.67) |
| Influenza A H3N2 Antibody | 2.60 (2.46 to 2.76) | 3.68 (3.49 to 3.87) | 3.16 (2.99 to 3.35) | 5.33 (5.04 to 5.64) | 3.40 (3.22 to 3.60) | 4.12 (3.90 to 4.36) |
| Influenza B/Victoria Antibody | 1.75 (1.67 to 1.84) | 2.22 (2.12 to 2.32) | 1.85 (1.78 to 1.93) | 2.47 (2.37 to 2.57) | 1.89 (1.82 to 1.97) | 2.35 (2.26 to 2.45) |
| Influenza B/Yamagata Antibody | 2.10 (1.99 to 2.22) | 2.63 (2.52 to 2.76) | 2.01 (1.93 to 2.10) | 2.79 (2.67 to 2.91) | 1.92 (1.85 to 2.00) | 2.20 (2.13 to 2.28) |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable AND/OR the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| Number of deaths | 1 | 5 | 2 | 3 | 1 | 3 |
| Number of deaths assessed by Sponsor as related to study drug | 0 | 0 | 0 | 0 | 0 | 0 |
| Number of deaths assessed by Investigator as related to study drug | 0 | 1 | 0 | 0 | 0 | 0 |
Collected over All-cause mortality and serious adverse events were collected from Day 1 through Day 181. Other (not including serious) unsolicited adverse events were collected up to 28 days after study injection (that is, Day 1 up to Day 29). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A: Fluarix QIV | 1/1,189 (0.1%) | 21/1,180 (1.8%) | 0/1,180 (0%) |
| Part A: mRNA-1010 | 5/1,225 (0.4%) | 27/1,220 (2.2%) | 0/1,220 (0%) |
| Part B: Fluarix QIV | 2/1,494 (0.1%) | 22/1,488 (1.5%) | 0/1,488 (0%) |
| Part B: mRNA-1010 | 3/1,500 (0.2%) | 25/1,492 (1.7%) | 0/1,492 (0%) |
| Part C: Fluzone HD QIV | 1/1,496 (0.1%) | 38/1,490 (2.6%) | 0/1,490 (0%) |
| Part C: mRNA-1010 | 3/1,507 (0.2%) | 41/1,502 (2.7%) | 0/1,502 (0%) |
| Event | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 |
|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 3/1180 | 1/1220 | 1/1488 | 2/1492 | 1/1490 | 3/1502 |
| CellulitisInfections and infestations | 0/1180 | 2/1220 | 1/1488 | 1/1492 | 0/1490 | 1/1502 |
| Deep vein thrombosisVascular disorders | 0/1180 | 2/1220 | 0/1488 | 0/1492 | 0/1490 | 1/1502 |
| DeathGeneral disorders | 0/1180 | 2/1220 | 1/1488 | 0/1492 | 0/1490 | 1/1502 |
| Acute myocardial infarctionCardiac disorders | 0/1180 | 1/1220 | 2/1488 | 0/1492 | 1/1490 | 2/1502 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/1180 | 1/1220 | 2/1488 | 0/1492 | 1/1490 | 2/1502 |
| NephrolithiasisRenal and urinary disorders | 0/1180 | 0/1220 | 0/1488 | 0/1492 | 2/1490 | 0/1502 |
| FallInjury, poisoning and procedural complications | 0/1180 | 1/1220 | 0/1488 | 0/1492 | 2/1490 | 0/1502 |
| Hip fractureInjury, poisoning and procedural complications | 0/1180 | 1/1220 | 0/1488 | 0/1492 | 2/1490 | 1/1502 |
| Subdural haematomaInjury, poisoning and procedural complications | 0/1180 | 0/1220 | 0/1488 | 0/1492 | 2/1490 | 0/1502 |
Randomization set included all participants who were randomly assigned to the study intervention, regardless of the participants' study intervention status in the study. Participants were analyzed according to the group to which they were randomized.
| Age, Categorical(Participants) | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 | Total |
|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 919 | 951 | 1494 | 1500 | 1 | 0 | 4865 |
| >=65 years | 270 | 274 | 0 | 0 | 1495 | 1507 | 3546 |
| Sex: Female, Male(Participants) | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 | Total |
|---|---|---|---|---|---|---|---|
| Female | 627 | 663 | 906 | 882 | 855 | 883 | 4816 |
| Male | 562 | 562 | 588 | 618 | 641 | 624 | 3595 |
| Ethnicity (NIH/OMB)(Participants) | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 226 | 262 | 392 | 406 | 456 | 451 | 2193 |
| Not Hispanic or Latino | 948 | 941 | 1083 | 1076 | 1025 | 1041 | 6114 |
| Unknown or Not Reported | 15 | 22 | 19 | 18 | 15 | 15 | 104 |
| Race/Ethnicity, Customized(Participants) | Part A: Fluarix QIV | Part A: mRNA-1010 | Part B: Fluarix QIV | Part B: mRNA-1010 | Part C: Fluzone HD QIV | Part C: mRNA-1010 | Total |
|---|---|---|---|---|---|---|---|
| Race — White | 856 | 922 | 970 | 1020 | 1224 | 1257 | 6249 |
| Race — Black or African American | 274 | 250 | 446 | 420 | 237 | 227 | 1854 |
| Race — Asian | 34 | 27 | 28 | 24 | 10 | 10 | 133 |
| Race — American Indian or Alaska Native | 5 | 7 | 12 | 12 | 9 | 4 | 49 |
| Race — Native Hawaiian or Other Pacific Islander | 1 | 3 | 4 | 4 | 0 | 2 | 14 |
| Race — Multiple | 11 | 11 | 18 | 6 | 6 | 2 | 54 |
| Race — Other | 3 | 3 | 7 | 11 | 4 | 1 | 29 |
| Race — Not Reported | 3 | 0 | 6 | 2 | 2 | 3 | 16 |
| Race — Unknown | 2 | 2 | 3 | 1 | 4 | 1 | 13 |
Showing the first 100 of 103 sites. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Apr 2023 to primary completion in Jun 2024, 14 months.
Results were first posted in Jul 2025, 1 year after primary completion.
Of 119 industry-sponsored phase 3 interventional studies under Influenza, Human, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 14. This study's 14 months is above that.
Counting every sponsor, half of 154 studies reached it within 8 months; a quarter within 4 and three quarters within 15.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: mRNA-1010 influenza vaccine